Mahkam Zanganeh

CIK: 0001507650

Transaction Breakdown

Open Market Buys (P)5 (22.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (4.5%)

Derivative conversions

Awards (A)12 (54.5%)

Compensation grants

Other (G, F, J, C, D, …)4 (18.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

PLSE

PULSE BIOSCIENCES, INC.

Director

SMMT

Summit Therapeutics Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (22 total)

SMMT
Summit Therapeutics Inc.
Jun 12, 2026
Purchase(P)
Indirect
3.8M shares at avg. $13.12$50.0M
PLSE
PULSE BIOSCIENCES, INC.
Jun 11, 2026
Award(A)
Stock Option (right to buy)
Direct
14.5K shares-
PLSE
PULSE BIOSCIENCES, INC.
Jun 11, 2026
Award(A)
Stock Option (right to buy)
Direct
30K shares-
SMMT
Summit Therapeutics Inc.
Jun 4, 2026
Purchase(P)
Indirect
100K shares at avg. $14.60$1.5M
SMMT
Summit Therapeutics Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Indirect
11.2K shares at avg. $8.76-
SMMT
Summit Therapeutics Inc.
Oct 21, 2025
Award(A)
Indirect
266.8K shares at avg. $18.74$5.0M
SMMT
Summit Therapeutics Inc.
Oct 21, 2025
Award(A)
Indirect
14M shares at avg. $18.74$262.0M
SMMT
Summit Therapeutics Inc.
Oct 21, 2025
Purchase(P)
Indirect
26.7K shares at avg. $18.74$500K
SMMT
Summit Therapeutics Inc.
Sep 11, 2025
Purchase(P)
Indirect
5K shares at avg. $18.07$90K
SMMT
Summit Therapeutics Inc.
Sep 10, 2025
Purchase(P)
Indirect
333.4K shares at avg. $17.68$5.9M
PLSE
PULSE BIOSCIENCES, INC.
Aug 15, 2025
Award(A)
Stock Option (right to buy)
Direct
24.1K shares-
PLSE
PULSE BIOSCIENCES, INC.
Aug 15, 2025
Award(A)
Stock Option (right to buy)
Direct
30K shares-
SMMT
Summit Therapeutics Inc.
May 30, 2025
Exercise(M)
Indirect
74.5K shares at avg. $2.64$197K
SMMT
Summit Therapeutics Inc.
Apr 29, 2025
Award(A)
Stock Option (right to buy)
Direct
1M shares-
SMMT
Summit Therapeutics Inc.
Apr 29, 2025
Award(A)
Stock Option (right to buy)
Direct
400K shares-
SMMT
Summit Therapeutics Inc.
Apr 29, 2025
Award(A)
Stock Option (right to buy)
Direct
9.6M shares-
SMMT
Summit Therapeutics Inc.
Apr 8, 2025
In-the-Money(X)
Indirect
4M shares at avg. $1.58$6.3M
PLSE
PULSE BIOSCIENCES, INC.
Feb 3, 2025
In-the-Money(X)
Direct
30.1K shares at avg. $11.00$331K
PLSE
PULSE BIOSCIENCES, INC.
Jan 24, 2025
In-the-Money(X)
Direct
30.1K shares at avg. $11.00$331K
SMMT
Summit Therapeutics Inc.
Jan 2, 2025
Award(A)
Stock Option (right to buy)
Indirect
10.7K shares at avg. $9.18-
SMMT
Summit Therapeutics Inc.
Oct 3, 2024
In-the-Money(X)
Indirect
315.7K shares at avg. $1.58$499K
SMMT
Summit Therapeutics Inc.
Sep 11, 2024
Award(A)
Indirect
44.1K shares at avg. $22.70$1000K

		Type	Shares	Price		Ownership
Jun 12, 2026	SMMT Summit Therapeutics Inc.	Purchase(P)	3,810,000	$13.12	$49,987,200	Indirect
Jun 11, 2026	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	14,504	-	-	Direct
Jun 11, 2026	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	30,000	-	-	Direct
Jun 4, 2026	SMMT Summit Therapeutics Inc.	Purchase(P)	100,000	$14.60	$1,460,000	Indirect
Jan 2, 2026	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	11,232	$8.76	-	Indirect
Oct 21, 2025	SMMT Summit Therapeutics Inc.	Award(A)	266,808	$18.74	$4,999,982	Indirect
Oct 21, 2025	SMMT Summit Therapeutics Inc.	Award(A)	13,980,789	$18.74	$261,999,986	Indirect
Oct 21, 2025	SMMT Summit Therapeutics Inc.	Purchase(P)	26,680	$18.74	$499,983	Indirect
Sep 11, 2025	SMMT Summit Therapeutics Inc.	Purchase(P)	5,000	$18.07	$90,350	Indirect
Sep 10, 2025	SMMT Summit Therapeutics Inc.	Purchase(P)	333,394	$17.68	$5,894,406	Indirect
Aug 15, 2025	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	24,134	-	-	Direct
Aug 15, 2025	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	30,000	-	-	Direct
May 30, 2025	SMMT Summit Therapeutics Inc.	Exercise(M)	74,545	$2.64	$196,799	Indirect
Apr 29, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	1,040,000	-	-	Direct
Apr 29, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	400,000	-	-	Direct
Apr 29, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	9,590,558	-	-	Direct
Apr 8, 2025	SMMT Summit Therapeutics Inc.	In-the-Money(X)	3,985,055	$1.58	$6,296,387	Indirect
Feb 3, 2025	PLSE PULSE BIOSCIENCES, INC.	In-the-Money(X)	30,121	$11.00	$331,331	Direct
Jan 24, 2025	PLSE PULSE BIOSCIENCES, INC.	In-the-Money(X)	30,121	$11.00	$331,331	Direct
Jan 2, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	10,724	$9.18	-	Indirect
Oct 3, 2024	SMMT Summit Therapeutics Inc.	In-the-Money(X)	315,681	$1.58	$498,776	Indirect
Sep 11, 2024	SMMT Summit Therapeutics Inc.	Award(A)	44,052	$22.70	$999,980	Indirect

1-22 of 22 transactions

About Zanganeh Mahkam

Zanganeh Mahkam (SEC CIK 0001507650) files insider reports with the SEC as Director of PULSE BIOSCIENCES, INC. (PLSE) and Co-Chief Executive Officer of Summit Therapeutics Inc. (SMMT).

Signal8 holds 14 ownership filings by Zanganeh Mahkam, all Form 4s, filed between Sep 13, 2024 and Jun 15, 2026. Those filings report 22 transactions, from Sep 11, 2024 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zanganeh Mahkam's filings is in MIAMI, FL.

Recent filings by Zanganeh Mahkam

Jun 12, 2026: Open-market purchase of SMMT shares (Form 4, code P).
Jun 11, 2026: Grants or awards of PLSE derivative securities (2 lines, Form 4, code A).
Jun 4, 2026: Open-market purchase of SMMT shares (Form 4, code P).
Jan 2, 2026: Grant or award of SMMT derivative securities (Form 4, code A).
Oct 21, 2025: Grants or awards of SMMT shares (2 lines, Form 4, code A).

Other insiders filing for PULSE BIOSCIENCES, INC. (PLSE)

Teplitsky Liane Rae, Chief Operating Officer
Skinner Jon, Chief Financial Officer
van den Broek Richard, Director
DUGGAN ROBERT W, Director
Soni Manmeet Singh, Director
Sainz Maria, Director

How to read Form 4 transaction codes